샘플 요청 목록

 카트 문의
시장보고서
상품코드
1469105

항비만제 시장(2024-2034년)

Anti-obesity Drugs Market Report 2024-2034
발행일: | 리서치사: Visiongain | 페이지 정보: 영문 310 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 항비만제 시장 규모는 2034년까지 연평균 21.2%의 성장률을 기록할 것으로 예상됩니다.

비만 증가:

지난 수십 년 동안 유전적, 환경적, 사회경제적, 문화적 요인이 복합적으로 작용하여 모든 연령대와 인구 집단에서 비만율이 급격히 증가했으며, 세계비만연맹(The World Obesity Federation)은 2020년까지 전 세계 약 7억 7,000만 명의 성인이 비만의 영향을 받을 것으로 추산하고 있습니다. 이 수치는 2030년까지 10억 명을 넘어설 것으로 예측하고 있습니다. 식습관의 변화, 좌식 생활습관, 도시화 및 세계화로 인해 건강에 해로운 식습관이 확산되고 신체 활동 수준이 감소하여 과도한 체중 증가와 비만과 관련된 건강 합병증을 유발하고 있습니다. 또한 비만은 단독 건강 상태일 뿐만 아니라 제2형 당뇨병, 심혈관 질환, 특정 암, 근골격계 질환 등 많은 만성 질환의 주요 위험 요소로, 인구 건강에 미치는 영향을 더욱 악화시키고 있습니다. 비만이 초래하는 결과는 개인의 건강상의 결과뿐만 아니라 의료비 증가, 생산성 저하, 삶의 질 저하 등 사회-경제적 부담으로까지 확대되고 있습니다. 비만의 다면적 요인을 해결하기 위해서는 건강한 라이프스타일을 장려하고, 영양가 높은 식품에 대한 접근성을 개선하며, 신체 활동을 지원하는 환경을 조성하기 위한 정책적 개입, 지역 사회 기반 이니셔티브, 교육 캠페인, 건강 관리 전략을 포함한 포괄적이고 다각적인 접근이 필요합니다. 비만의 근본 원인을 해결하고 효과적인 예방 및 치료 대책을 시행함으로써 이해관계자들은 비만의 확산을 완화하고 전 세계 건강과 복지에 미치는 막대한 영향을 줄일 수 있습니다.

의료비 지출 증가:

비만율이 전 세계적으로 지속적으로 증가함에 따라, 의료 시스템은 이러한 추세에 대응하기 위한 중재책에 점점 더 많은 자원을 할당하고 있습니다. 이러한 지출 증가는 보다 효과적인 항비만 약물을 개발하기 위한 R&D, 비만 관리 전략에 대한 의료진 교육 및 훈련, 환자 대상 아웃리치 및 지원 프로그램 등 다양한 측면에 걸쳐 이루어지고 있습니다. 또한 당뇨병, 심혈관 질환, 특정 암 등 비만과 관련된 건강 합병증의 경제적 부담은 이러한 다운스트림 건강 비용을 줄이기 위한 예방 및 치료 대책에 대한 투자의 필요성을 더욱 강조하고 있습니다. 또한, 의료 시스템이 예방적 개입과 만성질환 관리를 우선시하는 가치 기반 진료 모델로 전환함에 따라, 종합적인 비만 치료 계획에서 약물 치료의 역할이 더욱 중요해지고 있습니다. 항비만 약물의 초기 비용은 다소 비싸게 느껴질 수 있지만, 건강 개선과 비만 관련 합병증으로 인한 의료비 절감이라는 장기적인 잠재적 이익이 비용을 상회하는 경우가 많습니다. 전반적으로 항비만제 시장의 의료비 지출 증가는 시급한 공중보건 문제에 대한 전략적 투자를 반영하며, 이러한 추세가 가져올 광범위한 사회적, 경제적 영향을 완화하기 위해 의료 예산에서 비만 관리의 우선순위를 정하는 것이 중요하다는 것을 강조합니다.

세계 항비만제 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각 부문별·지역별 상세 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • 항비만제 분석
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
  • PEST 분석

제4장 항비만제 시장 분석 : 약제 유형별

  • 주요 조사 결과
  • 시장 매력도 지수
  • 시장 규모 추정과 예측
  • 처방전
  • OTC
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제5장 항비만제 시장 분석 : 작용기서별

  • 주요 조사 결과
  • 시장 매력도 지수
  • 시장 규모 추정과 예측
  • GLP-1 작용제
  • GIPR 길항제
  • 아밀린 수용체 작용제
  • 리파아제 억제제
  • SNRI
  • 기타
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제6장 항비만제 시장 분석 : 투여 경로별

  • 주요 조사 결과
  • 시장 매력도 지수
  • 시장 규모 추정과 예측
  • 경구
  • 정맥내
  • 피하
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제7장 항비만제 시장 분석 : 유통 채널별

  • 주요 조사 결과
  • 시장 매력도 지수
  • 시장 규모 추정과 예측
  • 병원 약국
  • 소매 약국
  • 온라인 약국
    • 시장 규모 추정과 예측 : 지역별
    • 시장 점유율 : 지역별

제8장 항비만제 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추정과 예측

제9장 북미의 항비만제 시장 분석

제10장 유럽의 항비만제 시장 분석

제11장 아시아태평양의 항비만제 시장 분석

제12장 라틴아메리카의 항비만제 시장 분석

제13장 중동 및 아프리카의 항비만제 시장 분석

제14장 기업 개요

  • 경쟁 상황
  • 전략적 전망
  • Arena Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Carmot Therapeutics, Inc.
  • CHEPLAPHARM Arzneimittel GmbH
  • CohBar, Inc.
  • Curaxx Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hanmi Pharm Co., Ltd.
  • Merck &Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS LLC
  • Zydus Lifesciences

제15장 결론과 제안

  • Visiongain에 의한 결론
  • 추천사항
ksm 24.05.07

The global Anti-obesity Drugs market is estimated to grow at a CAGR of 21.2% by 2034

The Anti-obesity Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Prevalence of Obesity

Over the past few decades, obesity rates have risen dramatically across all age groups and demographics, fuelled by a combination of genetic, environmental, socioeconomic, and cultural factors. The World Obesity Federation estimated that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Changes in dietary habits, sedentary lifestyles, urbanization, and globalization have contributed to the widespread adoption of unhealthy eating patterns and reduced physical activity levels, leading to excess weight gain and obesity-related health complications. Moreover, obesity is not only a standalone health condition but also a major risk factor for numerous chronic diseases, including type 2 diabetes, cardiovascular diseases, certain cancers, and musculoskeletal disorders, further exacerbating its impact on population health. The consequences of obesity extend beyond individual health outcomes to encompass societal and economic burdens, including increased healthcare costs, lost productivity, and diminished quality of life. Addressing the multifaceted drivers of obesity requires a comprehensive and multi-sectoral approach that encompasses policy interventions, community-based initiatives, education campaigns, and healthcare strategies aimed at promoting healthy lifestyles, improving access to nutritious foods, and creating supportive environments for physical activity. By tackling the root causes of obesity and implementing effective prevention and treatment measures, stakeholders can mitigate the escalating obesity epidemic and mitigate its far-reaching consequences on global health and well-being.

Rising Healthcare Expenditure

As obesity rates continue to climb globally, healthcare systems are increasingly allocating resources towards interventions aimed at combating this epidemic. This heightened expenditure encompasses various aspects, including research and development efforts to innovate new and more effective anti-obesity drugs, healthcare provider education and training on obesity management strategies, as well as patient outreach and support programs. Additionally, the economic burden of obesity-related health complications, such as diabetes, cardiovascular diseases, and certain cancers, further underscores the necessity of investing in preventive and therapeutic measures to mitigate these downstream health costs. Furthermore, as healthcare systems transition towards value-based care models that prioritize preventive interventions and chronic disease management, there is a growing emphasis on the role of pharmacotherapy in comprehensive obesity treatment plans. While the upfront costs of anti-obesity drugs may seem significant, they are often outweighed by the potential long-term benefits of improved health outcomes and reduced healthcare expenditures associated with obesity-related comorbidities. Overall, the rising healthcare expenditure in the anti-obesity drugs market reflects a strategic investment in addressing a pressing public health issue and underscores the importance of prioritizing obesity management within healthcare budgets to mitigate the broader societal and economic impacts of this epidemic.

What Questions Should You Ask before Buying a Market Research Report?

How is the Anti-obesity Drugs Market evolving?

What is driving and restraining the Anti-obesity Drugs Market?

How will each Anti-obesity Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Anti-obesity Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Anti-obesity Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Anti-obesity Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Anti-obesity Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Anti-obesity Drugs Market?

Where is the Anti-obesity Drugs Market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Anti-obesity Drugs Market today, and over the next 10 years:

Our 310-page report provides 134 tables and 191 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Anti-obesity Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-obesity drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Drug Type

Prescription

OTC

Mechanism of Action

Glucagon like Peptide GLP-1 Agonists

Gastric inhibitory Polypeptide Receptor (GIPR) Antagonist

Amylin Receptor Agonist

Lipase Inhibitors

Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)

Others

Route of Administration

Oral

Intravenous

Subcutaneous

Distribution channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Poland

Belgium

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Singapore

Taiwan

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-obesity Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Arena Pharmaceuticals Ltd.

Bayer AG

Boehringer Ingelheim International GmbH

Carmot Therapeutics, Inc.

CHEPLAPHARM Arzneimittel GmbH

CohBar, Inc.

Curaxx Pharmaceuticals LLC

Eisai Co., Ltd.

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharm Co., Ltd.

Merck & Co., Inc.

Novo Nordisk A/S

Pfizer Inc.

Rhythm Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

VIVUS LLC

Zydus Lifesciences

Overall world revenue for Anti-obesity Drugs Market, 2024 to 2034 in terms of value the market will surpass US$78,000 million in 2034, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-obesity Drugs Market, 2024 to 2034 report help you?

In summary, our 310-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Anti-obesity Drugs Market 2024 to 2034, with forecasts for drug type, Mechanism of action, route of administration, and distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Anti-obesity Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 17 of the major companies involved in the Anti-obesity Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Anti-obesity Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Anti-obesity Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Prevalence of Obesity
      • 3.2.1.2 Growing Awareness of Health Risks Associated with Obesity
      • 3.2.1.3 Technological Advancements
      • 3.2.1.4 Favourable Government Policies to Address Obesity Epidemic
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Adverse Drugs Reactions Associated with Anti-obesity Drugs
      • 3.2.2.2 Adherence to Weight Management Medications
      • 3.2.2.3 Lack of Access to Affordable Anti-obesity Drugs
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Increasing Number of Individuals Grappling with Obesity
      • 3.2.3.2 Automation in Drug Development Technologies
      • 3.2.3.3 Utilization of Digital Platforms to Enhance Patient Engagement
  • 3.3 Anti-obesity Drugs Analysis
    • 3.3.1 Top Anti-obesity Products, by Revenue
    • 3.3.2 Pipeline Analysis by Phase
    • 3.3.3 New Product Launches
  • 3.4 COVID-19 Impact Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Anti-obesity Drugs Market Analysis by Drug Type

  • 4.1 Key Findings
  • 4.2 Drug Type Segment: Market Attractiveness Index
  • 4.3 Anti-obesity Drugs Market Size Estimation and Forecast by Type
  • 4.4 Prescription
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 OTC
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Anti-obesity Drugs Market Analysis by Mechanism of Action

  • 5.1 Key Findings
  • 5.2 Drug Type Segment: Market Attractiveness Index
  • 5.3 Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 5.4 GLP-1 Agonists
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 GIPR Antagonists
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Amylin Receptor Agonist
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Lipase Inhibitors
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 SNRI's
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Others
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Million)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Anti-obesity Drugs Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 6.4 Oral
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Intravenous
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Subcutaneous
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Anti-obesity Drugs Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Hospital Pharmacies
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Retail Pharmacies
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Online Pharmacies
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)

8 Anti-obesity Drugs Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Anti-obesity Drugs Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Anti-obesity Drugs Market Attractiveness Index
  • 9.3 North America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 9.4 North America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 9.5 North America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 9.6 North America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 9.7 North America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 9.8 North America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 9.9 U.S. Anti-obesity Drugs Market Analysis
  • 9.10 Canada Anti-obesity Drugs Market Analysis

10 Europe Anti-obesity Drugs Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Anti-obesity Drugs Market Attractiveness Index
  • 10.3 Europe Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 10.4 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 10.5 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 10.6 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 10.7 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 10.8 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 10.9 Germany Anti-obesity Drugs Market Analysis
  • 10.10 France Anti-obesity Drugs Market Analysis
  • 10.11 UK Anti-obesity Drugs Market Analysis
  • 10.12 Italy Anti-obesity Drugs Market Analysis
  • 10.13 Spain Anti-obesity Drugs Market Analysis
  • 10.14 Russia Anti-obesity Drugs Market Analysis
  • 10.15 Poland Anti-obesity Drugs Market Analysis
  • 10.16 Belgium Anti-obesity Drugs Market Analysis
  • 10.17 Rest of Europe Anti-obesity Drugs Market Analysis

11 Asia Pacific Anti-obesity Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • 11.3 Asia Pacific Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 11.4 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 11.6 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 11.7 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.8 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.9 Japan Anti-obesity Drugs Market Analysis
  • 11.10 China Anti-obesity Drugs Market Analysis
  • 11.11 India Anti-obesity Drugs Market Analysis
  • 11.12 Australia Anti-obesity Drugs Market Analysis
  • 11.13 South Korea Anti-obesity Drugs Market Analysis
  • 11.14 Singapore Anti-obesity Drugs Market Analysis
  • 11.15 Taiwan Anti-obesity Drugs Market Analysis
  • 11.16 Rest of Asia Pacific Anti-obesity Drugs Market Analysis

12 Latin America Anti-obesity Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Anti-obesity Drugs Market Attractiveness Index
  • 12.3 Latin America Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 12.4 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 12.5 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 12.6 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 12.7 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.8 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.9 Brazil Anti-obesity Drugs Market Analysis
  • 12.10 Mexico Anti-obesity Drugs Market Analysis
  • 12.11 Argentina Anti-obesity Drugs Market Analysis
  • 12.12 Colombia Anti-obesity Drugs Market Analysis
  • 12.13 Rest of Latin America Anti-obesity Drugs Market Analysis

13 MEA Anti-obesity Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Anti-obesity Drugs Market Attractiveness Index
  • 13.3 MEA Anti-obesity Drugs Market by Country, 2024, 2029 & 2034 (US$ Million)
  • 13.4 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 13.5 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 13.6 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Mechanism of Action
  • 13.7 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.8 MEA Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.9 GCC Anti-obesity Drugs Market Analysis
  • 13.10 South Africa Anti-obesity Drugs Market Analysis
  • 13.11 Rest of MEA Anti-obesity Drugs Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2022
  • 14.2 Summary of all Strategic Outlook
  • 14.3 Arena Pharmaceuticals Ltd.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Bayer AG
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2023
      • 14.4.3.2 R&D, 2017-2023
      • 14.4.3.3 Regional Market Shares, 2023
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Boehringer Ingelheim International GmbH
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
      • 14.5.3.3 Regional Market Shares, 2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Carmot Therapeutics, Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Product Benchmarking
    • 14.6.4 Strategic Outlook
  • 14.7 CHEPLAPHARM Arzneimittel GmbH
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Product Benchmarking
    • 14.7.4 Strategic Outlook
  • 14.8 CohBar, Inc.
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
    • 14.8.4 Strategic Outlook
  • 14.9 Curaxx Pharmaceuticals LLC
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 Eisai Co., Ltd.
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2017-2022
      • 14.10.3.2 R&D, 2017-2022
      • 14.10.3.3 Regional Market Shares, 2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Eli Lilly and Co
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2023
      • 14.11.3.2 R&D, 2017-2023
      • 14.11.3.3 Regional Market Shares, 2023
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 F. Hoffmann-La Roche Ltd
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
    • 14.12.4 Product Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 GlaxoSmithKline Plc
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2017-2023
      • 14.13.3.2 R&D, 2017-2023
      • 14.13.3.3 Regional Market Shares, 2023
    • 14.13.4 Product Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 Hanmi Pharm Co., Ltd.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2017-2022
    • 14.14.4 Product Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Merck & Co., Inc.
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2017-2023
      • 14.15.3.2 R&D, 2017-2023
      • 14.15.3.3 Regional Market Shares, 2023
    • 14.15.4 Product Benchmarking
    • 14.15.5 Strategic Outlook
  • 14.16 Novo Nordisk A/S
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2017-2022
      • 14.16.3.2 R&D, 2017-2022
      • 14.16.3.3 Regional Market Shares, 2022
    • 14.16.4 Product Benchmarking
    • 14.16.5 Strategic Outlook
  • 14.17 Pfizer Inc.
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2017-2023
      • 14.17.3.2 R&D, 2017-2023
      • 14.17.3.3 Regional Market Shares, 2022
    • 14.17.4 Product Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Rhythm Pharmaceuticals, Inc.
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2017-2022
      • 14.18.3.2 R&D, 2017-2022
      • 14.18.3.3 Regional Market Shares, 2022
    • 14.18.4 Product Benchmarking
    • 14.18.5 Strategic Outlook
  • 14.19 Takeda Pharmaceutical Company Limited
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2017-2023
      • 14.19.3.2 R&D, 2017-2023
      • 14.19.3.3 Regional Market Shares, 2023
    • 14.19.4 Product Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 VIVUS LLC
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Financial Analysis
      • 14.20.3.1 Net Revenue, 2017-2023
      • 14.20.3.2 R&D, 2017-2019
      • 14.20.3.3 Regional Market Shares, 2023
    • 14.20.4 Product Benchmarking
    • 14.20.5 Strategic Outlook
  • 14.21 Zydus Lifesciences
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2017-2023
      • 14.21.3.2 R&D, 2017-2023
      • 14.21.3.3 Regional Market Shares, 2023
    • 14.21.4 Product Benchmarking
    • 14.21.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제